The global Guillain-Barre syndrome (GBS) drugs market is anticipated to grow at a significant CAGR during the forecast period. GBS is a rare disorder that causes the body’s immune system to attack nerves. The first sign of symptoms includes weakness and tingling in the extremities, however, these sensations can quickly spread which can paralyze the whole body. The major factor driving the market growth is the increasing prevalence of GBS.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/guillain-barre-syndrome-drugs-market
According to the Rare Disease Organization, GBS affects about one or two people each year in every 100,000 population. Additionally, as per the Centre for Diseases Control and Prevention (CDC), an estimated 3,000 to 6,000 people are diagnosed with GBS each year in the US. Moreover, as per the same source, GBS is more common in men and adults older than 50 in the US. Furthermore, 40% of the GBS are triggered by Campylobacter infection in the US. Hence, the rising prevalence of GBS is driving the demand for the GBS drugs for treatment which in turn is driving the growth of the market.
Some major players operating in the market include Akari Therapeutics plc, Annexon Inc, and Hansa Biopharma AB, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2019, Annexon Biosciences announced that it has received fast track designation for ANX005 from the US FDA. It is a drug used for the novel treatment of Guillain-Barre syndrome.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Product
o By Application
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Akari Therapeutics plc, Annexon Inc, and Hansa Biopharma AB, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Guillain-Barre Syndrome Drugs Market Report by Segment
By Product
- Coversin
- Immune Globulin
- Others
By Application
- Clinic
- Hospital
- Others
A full report of Guillain-Barre Syndrome Drugs Market is available at: https://www.omrglobal.com/industry-reports/guillain-barre-syndrome-drugs-market
Guillain-Barre Syndrome Drugs Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Akari Therapeutics plc
- Annexon Inc
- Hansa Biopharma AB
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
